Our results demonstrated significantly lower I-FABP levels in healthy subjects than lean NAFLD patients (p = 0.002), as well as between healthy individuals and non-lean NAFLD patients (p = 0.004, Figure 7a). This evidence concerns the gene FABP2 and metabolic dysfunction-associated steatotic liver disease.